Sawczyńska Katarzyna, Wrona Paweł, Wróbel Dominik, Zdrojewska Kaja, Sarba Paulina, Giełczyński Mateusz, Włodarczyk Ewa, Popiela Tadeusz, Słowik Agnieszka, Krzanowski Marcin
Department of Neurology, University Hospital in Kraków, Kraków, Poland; Department of Neurology, Jagiellonian University Medical College, Kraków, Poland.
Department of Neurology, University Hospital in Kraków, Kraków, Poland
Pol Arch Intern Med. 2024 Sep 27;134(9). doi: 10.20452/pamw.16800. Epub 2024 Jul 10.
Chronic kidney disease (CKD) is a risk factor of acute ischemic stroke (AIS). Outcomes of treatment with mechanical thrombectomy (MT) in patients with CKD seem to be poorer than in the general population. Long‑term follow‑up studies are lacking.
Our aim was to asses short- and long‑term outcomes (up to 365 days after stroke) in MT‑treated AIS patients with concomitant CKD.
The study included all AIS patients treated with MT at the Comprehensive Stroke Center in Kraków, Poland, from 2019 to 2021. The patients were divided into the CKD group (best glomerular filtration rate [GFR] during hospitalization <60 ml/min/1.73 m2 or diagnosed CKD) and the controls. In‑hospital, 90‑day, and 365‑day mortality and rate of good functional outcomes (defined as modified Rankin Scale ≤2) were compared between the CKD patients and controls as well as between patients with CKD stages 1-3 (GFR ≥30 ml/min/1.73 m2) and 4-5 (GFR <30 ml/min/1.73 m2). Factors associated with the abovementioned outcomes were identified using univariable logistic regression analyses and then added to multivariable analyses.
The CKD patients had higher 90- and 365‑day mortality and lower 90- and 365‑day good functional outcome rates than the controls. The patients with CKD stage 4-5 had significantly higher in‑hospital, 90‑day, and 365‑day mortality than the patients with CKD stage 1-3. Neither CKD nor its late stages (4-5) were independently associated with short- and long‑term mortality and functional outcomes of MT.
MT outcomes in CKD patients are worse, especially in advanced stages of the disease, but CKD is not independently associated with poor prognosis. CKD alone should not be a contraindication for MT in otherwise eligible patients, although patients with impaired kidney function require more careful postprocedural monitoring.
慢性肾脏病(CKD)是急性缺血性卒中(AIS)的一个危险因素。CKD患者接受机械取栓术(MT)治疗的结果似乎比普通人群更差。目前缺乏长期随访研究。
我们的目的是评估接受MT治疗的合并CKD的AIS患者的短期和长期预后(卒中后长达365天)。
该研究纳入了2019年至2021年在波兰克拉科夫综合卒中中心接受MT治疗的所有AIS患者。患者被分为CKD组(住院期间最佳肾小球滤过率[GFR]<60 ml/min/1.73 m²或已确诊CKD)和对照组。比较CKD患者与对照组以及CKD 1-3期(GFR≥30 ml/min/1.73 m²)和4-5期(GFR<30 ml/min/1.73 m²)患者的住院、90天和365天死亡率以及良好功能结局率(定义为改良Rankin量表≤2)。使用单变量逻辑回归分析确定与上述结局相关的因素,然后将其纳入多变量分析。
与对照组相比,CKD患者的90天和365天死亡率更高,90天和365天良好功能结局率更低。CKD 4-5期患者的住院、90天和365天死亡率显著高于CKD 1-3期患者。CKD及其晚期(4-5期)均与MT的短期和长期死亡率及功能结局无独立相关性。
CKD患者的MT结局更差,尤其是在疾病晚期,但CKD与不良预后无独立相关性。对于其他方面符合条件的患者,单纯CKD不应成为MT的禁忌证,尽管肾功能受损的患者术后需要更密切的监测。